Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10942602rdf:typepubmed:Citationlld:pubmed
pubmed-article:10942602lifeskim:mentionsumls-concept:C0596981lld:lifeskim
pubmed-article:10942602lifeskim:mentionsumls-concept:C0031715lld:lifeskim
pubmed-article:10942602lifeskim:mentionsumls-concept:C0079183lld:lifeskim
pubmed-article:10942602lifeskim:mentionsumls-concept:C0033414lld:lifeskim
pubmed-article:10942602lifeskim:mentionsumls-concept:C0699900lld:lifeskim
pubmed-article:10942602lifeskim:mentionsumls-concept:C0243125lld:lifeskim
pubmed-article:10942602lifeskim:mentionsumls-concept:C0205087lld:lifeskim
pubmed-article:10942602pubmed:issue1lld:pubmed
pubmed-article:10942602pubmed:dateCreated2000-9-20lld:pubmed
pubmed-article:10942602pubmed:abstractTextProliferating myoblasts already express MyoD before the induction of differentiation. Overexpression of MyoD in normal and transformed cell lines was shown to block cells from entering S phase, suggesting that the MyoD growth suppressive effect must be tightly controlled in growing myoblasts. Here we show that during G1 phase, but not in G2, MyoD abundance is down-regulated by the ubiquitin-proteasome pathway through phosphorylation of serine 200. Roscovitine, a specific inhibitor of cyclin-Cdk2 complexes, prevents both phosphorylation and degradation of MyoD in G1. Inhibition of the ubiquitin-dependent proteasome pathway by MG132 results in stabilization of MyoD-wt, with little effect on a MyoD mutant where serine 200 is replaced by an alanine. Our results show that MyoD Ser200 is the substrate for phosphorylation by cyclin E-Cdk2 stimulating its degradation by the ubiquitin-proteasome system which controls MyoD levels in G1. Phosphorylation/degradation of MyoD at the end of G1 thus represents the regulatory checkpoint in growing myoblasts allowing progression into S phase in a manner similar to the recently examplified cdk2-phosphorylation/degradation of p27(Kip1).lld:pubmed
pubmed-article:10942602pubmed:languageenglld:pubmed
pubmed-article:10942602pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10942602pubmed:citationSubsetIMlld:pubmed
pubmed-article:10942602pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10942602pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10942602pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10942602pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10942602pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10942602pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10942602pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10942602pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10942602pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10942602pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10942602pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10942602pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10942602pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10942602pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10942602pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10942602pubmed:statusMEDLINElld:pubmed
pubmed-article:10942602pubmed:monthAuglld:pubmed
pubmed-article:10942602pubmed:issn0014-4827lld:pubmed
pubmed-article:10942602pubmed:authorpubmed-author:LeibovitchS...lld:pubmed
pubmed-article:10942602pubmed:authorpubmed-author:LeibovitchM...lld:pubmed
pubmed-article:10942602pubmed:authorpubmed-author:FernandezAAlld:pubmed
pubmed-article:10942602pubmed:authorpubmed-author:MeijerLLlld:pubmed
pubmed-article:10942602pubmed:authorpubmed-author:DucommunBBlld:pubmed
pubmed-article:10942602pubmed:authorpubmed-author:KitzmannMMlld:pubmed
pubmed-article:10942602pubmed:authorpubmed-author:TintignacL...lld:pubmed
pubmed-article:10942602pubmed:copyrightInfoCopyright 2000 Academic Press.lld:pubmed
pubmed-article:10942602pubmed:issnTypePrintlld:pubmed
pubmed-article:10942602pubmed:day25lld:pubmed
pubmed-article:10942602pubmed:volume259lld:pubmed
pubmed-article:10942602pubmed:ownerNLMlld:pubmed
pubmed-article:10942602pubmed:authorsCompleteYlld:pubmed
pubmed-article:10942602pubmed:pagination300-7lld:pubmed
pubmed-article:10942602pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:10942602pubmed:meshHeadingpubmed-meshheading:10942602...lld:pubmed
pubmed-article:10942602pubmed:meshHeadingpubmed-meshheading:10942602...lld:pubmed
pubmed-article:10942602pubmed:meshHeadingpubmed-meshheading:10942602...lld:pubmed
pubmed-article:10942602pubmed:meshHeadingpubmed-meshheading:10942602...lld:pubmed
pubmed-article:10942602pubmed:meshHeadingpubmed-meshheading:10942602...lld:pubmed
pubmed-article:10942602pubmed:meshHeadingpubmed-meshheading:10942602...lld:pubmed
pubmed-article:10942602pubmed:meshHeadingpubmed-meshheading:10942602...lld:pubmed
pubmed-article:10942602pubmed:meshHeadingpubmed-meshheading:10942602...lld:pubmed
pubmed-article:10942602pubmed:meshHeadingpubmed-meshheading:10942602...lld:pubmed
pubmed-article:10942602pubmed:meshHeadingpubmed-meshheading:10942602...lld:pubmed
pubmed-article:10942602pubmed:meshHeadingpubmed-meshheading:10942602...lld:pubmed
pubmed-article:10942602pubmed:meshHeadingpubmed-meshheading:10942602...lld:pubmed
pubmed-article:10942602pubmed:meshHeadingpubmed-meshheading:10942602...lld:pubmed
pubmed-article:10942602pubmed:meshHeadingpubmed-meshheading:10942602...lld:pubmed
pubmed-article:10942602pubmed:meshHeadingpubmed-meshheading:10942602...lld:pubmed
pubmed-article:10942602pubmed:meshHeadingpubmed-meshheading:10942602...lld:pubmed
pubmed-article:10942602pubmed:meshHeadingpubmed-meshheading:10942602...lld:pubmed
pubmed-article:10942602pubmed:meshHeadingpubmed-meshheading:10942602...lld:pubmed
pubmed-article:10942602pubmed:meshHeadingpubmed-meshheading:10942602...lld:pubmed
pubmed-article:10942602pubmed:meshHeadingpubmed-meshheading:10942602...lld:pubmed
pubmed-article:10942602pubmed:meshHeadingpubmed-meshheading:10942602...lld:pubmed
pubmed-article:10942602pubmed:meshHeadingpubmed-meshheading:10942602...lld:pubmed
pubmed-article:10942602pubmed:year2000lld:pubmed
pubmed-article:10942602pubmed:articleTitleCyclin E-cdk2 phosphorylation promotes late G1-phase degradation of MyoD in muscle cells.lld:pubmed
pubmed-article:10942602pubmed:affiliationLaboratoire de Génétique Oncologique, Institut Gustave Roussy, Villejuif, 94805, France.lld:pubmed
pubmed-article:10942602pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10942602pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10942602lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10942602lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10942602lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10942602lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10942602lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10942602lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10942602lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10942602lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10942602lld:pubmed